Marina De Smet - Concepedia

Concepedia

Author

Marina De Smet

Merck & Co., Inc., Rahway, NJ, USA (United States)

Also Known As

Marina De Smet, Marina de Smet, Marina. De Smet

24

Publications

1.9K

Citations

19

H-Index

57

Concepts

All Affiliations

Merck & Co., Inc., Rahway, NJ, USA (United States)Boehringer Ingelheim (Germany)United States Military Academy Ghent University Hospital Boehringer Ingelheim (Belgium)

MD

About

Marina De Smet is an author at Merck & Co., Inc., Rahway, NJ, USA (United States) specializing in medicine, pharmacology, and pharmacotherapy.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	12	12	820
2	Engineering	1	1	63
3	Health Sciences	1	1	17
4	Natural Sciences	1	1	19
5	Public Health	1	1	33

Marina De Smet

×

21

Publications

1.9K

Citations

18

H-Index

	Year	Citations
Effect of Single Oral Doses of Sitagliptin, a Dipeptidyl Peptidase-4 Inhibitor, on Incretin and Plasma Glucose Levels after an Oral Glucose Tolerance Test in Patients with Type 2 Diabetes Gary Herman, Arthur Bergman, Catherine Stevens, The Journal of Clinical Endocrinology & Metabolism	2006	498
Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: A double-blind, randomized, placebo-controlled study in healthy male volunteers Arthur Bergman, Catherine Stevens, Yanyan Zhou, Clinical Therapeutics Pharmacological StudyMedicineHealthy Male VolunteersPlacebo-controlled StudyPharmacotherapy	2006	265
The effect of MK-0591, a novel 5-lipoxygenase activating protein inhibitor, on leukotriene biosynthesis and allergen-induced airway responses in asthmatic subjects in vivo Zuzana Diamant, Mieke Timmers, H. van der Veen, Journal of Allergy and Clinical Immunology InflammationAsthmaProtein InhibitorAllergyLeukotriene Biosynthesis	1995	157
Prevention of cisplatin‐induced acute and delayed emesis by the selective neurokinin‐1 antagonists, L‐758,298 and MK‐869 Simon Van Belle, M. Lichinitser, Rudolph M. Navari, Cancer	2002	147
Pharmacokinetics, Bioavailability, and Safety of Montelukast Sodium (MK-0476) in Healthy Males and Females Haiyung Cheng, Jonathan A. Leff, Raju D. Amin, Pharmaceutical Research	1996	139
Effect of Age and Renal Function on Idarucizumab Pharmacokinetics and Idarucizumab-Mediated Reversal of Dabigatran Anticoagulant Activity in a Randomized, Double-Blind, Crossover Phase Ib Study Stephan Glund, Joachim Stangier, Joanne van Ryn, Clinical Pharmacokinetics	2016	85
Idarucizumab, a Specific Antidote for Dabigatran: Immediate, Complete and Sustained Reversal of Dabigatran Induced Anticoagulation in Elderly and Renally Impaired Subjects Stephan Glund, Joachim Stangier, Michael Schmohl, Blood	2014	70
Lack of effect of aprepitant on the pharmacokinetics of docetaxel in cancer patients Peter Nygren, Kenneth R. Hande, Kevin J. Petty, Cancer Chemotherapy and Pharmacology Molecular PharmacologyOncologyPharmacological StudyMedicineClinical Pharmacology	2005	65
Minimal Effects of Ritonavir and Efavirenz on the Pharmacokinetics of Raltegravir Marian Iwamoto, Larissa Wenning, Amelia S. Petry, Antimicrobial Agents and Chemotherapy Plasma ConcentrationsHealthy SubjectsPharmacological StudyMinimal EffectsHuman Retrovirus	2008	65
Separation strategy of multicomponent mixtures by liquid chromatography with a single stationary phase and a limited number of mobile phase solvents Marina De Smet, G. Hoogewijs, Marc L Puttemans, Analytical Chemistry EngineeringAltmetric Attention ScoreOrganic ChemistryChemical Engineering SeparationsChemistry	1984	63

Page 1